| Autor: |
Xavier Thomas, Marica Laurino, sandrine loron, marie-virginie larcher, gaëlle fossard, mohamed elhamri, alexandre deloire, marie balsat, fiorenza barraco, hélène labussière, sophie ducastelle, myriam renault, eric wattel, maël heiblig, gilles salles |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Mediterranean Journal of Hematology and Infectious Diseases, Vol 12, Iss 1 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
2035-3006 |
| DOI: |
10.4084/mjhid.2020.020 |
| Popis: |
One-hundred and four adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) were treated with fractionated doses of gemtuzumab ozogamicin (GO) at one-single French center over a 10-year period. We attempted to define predictive factors for response and survival. The overall response rate was 70% (86% in newly diagnosed and 67% in relapsed/refractory AML). Disease-free survival (DFS) and overall survival at 3 years after GO treatment was 31% and 29%, respectively. Mortality during induction was 7%. Among remitters, allogeneic hematopoietic stem cell transplantation can be performed in 33 cases (45%). DFS at 3 years was 54%. Incidences of transplant-related mortality, grade ≥ 3 acute graft-versus-host (GvH) disease, and extensive chronic GvH disease were 15%, 12%, and 27%, respectively.No sinusoidal obstruction syndromes were reported among allografted patients as among the other patients in the studied cohort. GO-based chemotherapy is a viable option for treatment of newly diagnosed and relapsed/refractory AML patients, and is a feasible schedule as a bridge to allogeneic transplant. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
